Why the study?
Does coagulation factor XI protect against diastolic dysfunction in mice?
Does coagulation factor XI protect against diastolic dysfunction in mice?
Coagulation factor XI has a novel protective role against heart injury and diastolic dysfunction that is distinct from its role in coagulation.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for diastolic dysfunction; leaves open FXI as a preclinical research target beyond coagulation.
Tissue-tissue communication by endocrine factors is a vital mechanism for physiologic homeostasis. A systems genetics analysis of transcriptomic and functional data from a cohort of diverse, inbred strains of mice predicted that coagulation factor XI (FXI), a liver-derived protein, protects against diastolic dysfunction, a key trait of heart failure with preserved ejection fraction. This was confirmed using gain- and loss-of-function studies, and FXI was found to activate the bone morphogenetic protein (BMP)-SMAD1/5 pathway in the heart. The proteolytic activity of FXI is required for the cleavage and activation of extracellular matrix-associated BMP7 in the heart, thus inhibiting genes involved in inflammation and fibrosis. Our results reveal a protective role of FXI in heart injury that is distinct from its role in coagulation.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: